Compare Elder Pharma with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs ALKEM LABORATORIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA ALKEM LABORATORIES ELDER PHARMA/
ALKEM LABORATORIES
 
P/E (TTM) x -0.2 - - View Chart
P/BV x 0.1 6.4 1.6% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ELDER PHARMA   ALKEM LABORATORIES
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
ALKEM LABORATORIES
Mar-16
ELDER PHARMA/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3801,589 23.9%   
Low Rs1881,232 15.3%   
Sales per share (Unadj.) Rs491.2417.5 117.7%  
Earnings per share (Unadj.) Rs-3.256.3 -5.7%  
Cash flow per share (Unadj.) Rs14.464.7 22.3%  
Dividends per share (Unadj.) Rs012.70 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs376.5292.9 128.5%  
Shares outstanding (eoy) m20.54119.57 17.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.63.4 17.1%   
Avg P/E ratio x-89.325.1 -356.3%  
P/CF ratio (eoy) x19.721.8 90.4%  
Price / Book Value ratio x0.84.8 15.7%  
Dividend payout %022.6 0.0%   
Avg Mkt Cap Rs m5,833168,653 3.5%   
No. of employees `000NANA-   
Total wages/salary Rs m2,1799,171 23.8%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m10,08949,915 20.2%  
Other income Rs m2571,645 15.6%   
Total revenues Rs m10,34651,561 20.1%   
Gross profit Rs m-7928,482 -9.3%  
Depreciation Rs m3611,006 35.9%   
Interest Rs m2,756671 411.0%   
Profit before tax Rs m-3,6538,451 -43.2%   
Minority Interest Rs m0-114 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m1251,606 7.8%   
Profit after tax Rs m-656,731 -1.0%  
Gross profit margin %-7.817.0 -46.2%  
Effective tax rate %-3.419.0 -18.0%   
Net profit margin %-0.613.5 -4.8%  
BALANCE SHEET DATA
Current assets Rs m9,24027,062 34.1%   
Current liabilities Rs m9,99815,324 65.2%   
Net working cap to sales %-7.523.5 -31.9%  
Current ratio x0.91.8 52.3%  
Inventory Days Days4667 69.6%  
Debtors Days Days6041 145.2%  
Net fixed assets Rs m10,12412,610 80.3%   
Share capital Rs m206239 86.0%   
"Free" reserves Rs m5,58234,490 16.2%   
Net worth Rs m7,73435,027 22.1%   
Long term debt Rs m4,8891,212 403.5%   
Total assets Rs m22,88254,387 42.1%  
Interest coverage x-0.313.6 -2.4%   
Debt to equity ratio x0.60 1,827.6%  
Sales to assets ratio x0.40.9 48.0%   
Return on assets %11.813.6 86.4%  
Return on equity %-0.819.2 -4.4%  
Return on capital %22.324.9 89.8%  
Exports to sales %3.012.9 23.5%   
Imports to sales %0.43.1 13.8%   
Exports (fob) Rs m3076,461 4.7%   
Imports (cif) Rs m431,540 2.8%   
Fx inflow Rs m3076,563 4.7%   
Fx outflow Rs m1253,012 4.2%   
Net fx Rs m1813,552 5.1%   
CASH FLOW
From Operations Rs m11,7547,259 161.9%  
From Investments Rs m-5611,864 -30.1%  
From Financial Activity Rs m-6,762-9,273 72.9%  
Net Cashflow Rs m4,432-150 -2,954.5%  

Share Holding

Indian Promoters % 39.6 66.9 59.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 33.1 22.7%  
FIIs % 16.8 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 0.0 -  
Shareholders   16,479 68,381 24.1%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   J.B.CHEMICALS  SUVEN LIFESCIENCES  CIPLA  CADILA HEALTHCARE  VENUS REMEDIES  

Compare ELDER PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower; Metal and Banking Stocks Drag(09:30 am)

Asian share markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 1% while the Hang Seng is up 1.1%.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 5-YR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS